Business & regional news

Month Year

Email alerts

Jan 17, 2025

Medtronic drives continued momentum with new data and case presentations for Affera™ Mapping and Ablation System and PulseSelect™ at AF Symposium

Data include durability of PulseSelect integrated with the Affera system, same day discharge and zero fluoroscopy with Affera and Sphere-9™ Catheter

Highlights underscore positive momentum of commercial launch of Affera in the U.S. and continued strong adoption of PulseSelect globally

Real-world use continues to demonstrate safety, efficacy and efficiency of both PFA technologies amid global expansion
- Cardiac Ablation Solutions
Oct 11, 2024

Medtronic announces FDA approval for early feasibility trial of Affera™ Mapping and Ablation System with Sphere-9™ Catheter for the treatment of ventricular tachycardia

The VT research will provide important clinical evidence in an underserved patient population
- Cardiac Ablation Solutions
Aug 22, 2024

First enrollment completed in REAL-Pulse, PulseSelect™ pulsed field ablation system global registry, as demand and adoption continue to increase

Post-market data collection will add real-world experience to established safety, efficacy, and efficiency evidence profile
- Cardiac Ablation Solutions
May 10, 2024

PulseSelect™ pulsed field ablation system receives approval in Japan, broadening global impact of paradigm-shifting AFib treatment
- Cardiac Ablation Solutions
Feb 1, 2024

Medtronic announces successful first cases using PulseSelect™ pulsed field ablation system

Physician feedback confirms clinical evidence: safe, efficient, and effective treatment offers most versatile new option for atrial fibrillation
- Cardiac Ablation Solutions

Show per page

Su	Mo	Tu	We	Th	Fr	Sa

Su	Mo	Tu	We	Th	Fr	Sa